AII antagonists in hypertension, heart failure, and diabetic nephropathy: focus on losartan

References

• Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289:2560–72
   PubMed Web of Science ®Google Scholar
• Cushman WC. The burden of uncontrolled hypertension: morbidity and mortality associated with disease progression. J Clin Hypertens (Greenwich) 2003;5:14–22
   PubMedGoogle Scholar
• Jafar TH, Schmid CH, Landa M, Giatras I, Toto R, Remuzzi, G et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73–87
   PubMed Web of Science ®Google Scholar
• Lever AF, Beevers DG, Hole DJ, Isles CG, Meredith PA, Murray LS, et al. Mortality amongst patients of the Glasgow Blood Pressure Clinic was high in the 1970s and 80s but has fallen since, why? Clin Exp Hypertens 1999;21:553–62
   PubMed Web of Science ®Google Scholar
• Pahor M, Psaty BM, Alderman MH, Applegate WB, Williamson JD, Furberg CD. Therapeutic benefits of ACE inhibitors and other antihypertensive drugs in patients with type 2 diabetes. Diabetes Care 2000;23:888–92
   PubMed Web of Science ®Google Scholar
• Psaty BM, Lumley T, Furberg CD, Schellenbaum G, Pahor M, Alderman MH, et al. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis. JAMA 2003;289:2534–44
   PubMed Web of Science ®Google Scholar
• Psaty BM, Heckbert SR, Koepsell TD, Siscovick DS, Raghunathan TE, Weiss NS, et al. The risk of myocardial infarction associated with antihypertensive drug therapies. JAMA 1995;274:620–5
   PubMed Web of Science ®Google Scholar
• Sica DA, Douglas JG. The African American Study of Kidney Disease and Hypertension (AASK): new findings. J Clin Hypertens (Greenwich) 2001;3:244–51
   PubMedGoogle Scholar
• Wright JT, Jr., Agodoa L, Contreras G, Greene T, Douglas JG, Lash J, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med 2002;162:1636–43
   PubMed Web of Science ®Google Scholar
• Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002;288:2998–3007
   PubMed Web of Science ®Google Scholar
• Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288:2981–97
   PubMed Web of Science ®Google Scholar
• Alderman MH. ALLHAT and beyond. Am J Hypertens 2003;16:512–4
   PubMed Web of Science ®Google Scholar
• Flack JM, Nasser SA. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. Curr Hypertens Rep 2003;5:189–91
   Google Scholar
• Beevers DG, Lee KW, Lip GY. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT): ALL predictable, and no big surprise out of a HAT? J Hum Hypertens 2003;17:367–72
   Google Scholar
• Laragh JH, Sealey JE. Relevance of the plasma renin hormonal control system that regulates blood pressure and sodium balance for correctly treating hypertension and for evaluating ALLHAT. Am J Hypertens 2003;16:407–15
   PubMed Web of Science ®Google Scholar
• Nilsson P. Conclusions in an Australian trial differ from those in the ALLHAT trial: ACE inhibitors are more effective than thiazides in elderly men with hypertension. Lakartidningen 2003;100:1118–20
   PubMedGoogle Scholar
• Douglas JG, Agodoa L. ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial. Kidney Int 2003;(Suppl):S74–S76
   Google Scholar
• Douglas JG, Bakris GL, Epstein M, Ferdinand KC, Ferrario C, Flack JM, et al. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med 2003;163:525–41
   PubMed Web of Science ®Google Scholar
• Kannel WB, Wolf PA, Verter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. JAMA 1970;214:301–10
   PubMed Web of Science ®Google Scholar
• Kannel WB, Gordon T, Castelli WP, Margolis JR. Electrocardiographic left ventricular hypertrophy and risk of coronary heart disease. The Framingham study. Ann Intern Med 1970;72:813–22
   PubMedGoogle Scholar
• Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990;322:1561–6
   Google Scholar
• Muiesan ML, Salvetti M, Rizzoni D, Monteduro C, Castellano M, Agabiti-Rosei E. Persistence of left ventricular hypertrophy is a stronger indicator of cardiovascular events than baseline left ventricular mass or systolic performance: 10 years of follow-up. J Hypertens 1996;14(Suppl):S43–S49
   Google Scholar
• Diez J, Lopez B, Gonzalez A, Querejeta R. Clinical aspects of hypertensive myocardial fibrosis. Curr Opin Cardiol 2001;16:328–35
   PubMed Web of Science ®Google Scholar
• Diez J, Querejeta R, Lopez B, Gonzalez A, Larman M, Martinez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation 2002;105:2512–7
   Google Scholar
• Lopez B, Gonzalez A, Varo N, Laviades C, Querejeta R, Diez J. Biochemical assessment of myocardial fibrosis in hypertensive heart disease. Hypertension 2001;38:1222–6
   PubMed Web of Science ®Google Scholar
• Baker KM, Booz GW, Dostal DE. Cardiac actions of angiotensin II: role of an intracardiac renin-angiotensin system. Ann Rev Physiol 1992;54:227–41
   Google Scholar
• Segar JL, Dalshaug GB, Bedell KA, Smith OM, Scholz TD. Angiotensin II in cardiac pressure-overload hypertrophy in fetal sheep. Am J Physiol Regul Integr Comp Physiol 2001;281:R2037–R2047
   PubMedGoogle Scholar
• Rockman HA, Wachhorst SP, Mao L, Ross J, Jr. ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice. Am J Physiol 1994;266:H2468–H2475
   Google Scholar
• Arakawa K, Urata H. Hypothesis regarding the pathophysiological role of alternative pathways of angiotensin II formation in atherosclerosis. Hypertension 2000;36:638–41
   PubMed Web of Science ®Google Scholar
• Urata H. Chymase in ischemic cardiovascular diseases. Nippon Rinsho 2003;61(Suppl 5):860–6.
   PubMedGoogle Scholar
• Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:995–1003
   PubMed Web of Science ®Google Scholar
• Dahlof B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al. The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997;10:705–13
   PubMed Web of Science ®Google Scholar
• Lindholm LH, Ibsen H, Dahlof B, Devereux RB, Beevers G, de Faire U, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359:1004–10
   Google Scholar
• Kjeldsen SE, Dahlof B, Devereux RB, Julius S, Aurup P, Edelman J, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) substudy. JAMA 2002;288:1491–8
   PubMed Web of Science ®Google Scholar
• Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003;21:875–86
   PubMed Web of Science ®Google Scholar
• Tedesco MA, Ratti G, Aquino D, Limongelli G, Di Salvo G, Mennella S, et al. Effects of losartan on hypertension and left ventricular mass: a long-term study. J Hum Hypertens 1998;12:505–10
   PubMed Web of Science ®Google Scholar
• Tedesco MA, Ratti G, Aquino D, Caccavale A, Acitorio M, Rocereto A, et al. The effectiveness and tolerability of losartan and effect on left ventricular mass in patients with essential hypertension. Cardiologia 1998;43:53–9
   PubMedGoogle Scholar
• Thurmann PA, Kenedi P, Schmidt A, Harder S, Rietbrock N. Influence of the angiotensin II antagonist valsartan on left ventricular hypertrophy in patients with essential hypertension. Circulation 1998;98:2037–42
   Google Scholar
• Messerli FH. The LIFE study: the straw that should break the camel’s back. Eur Heart J 2003;24:487–9
   PubMedGoogle Scholar
• Messerli FH, Mehra MR. Crumbling of left ventricular hypertrophy as a surrogate end point (the Losartan for Intervention for Endpoint Reduction in Hypertension [LIFE] Study). Am J Cardiol 2002;90:1133–4
   PubMed Web of Science ®Google Scholar
• [No author listed]. Timolol-induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. N Engl J Med 1981;304: 801–7
   Google Scholar
• [No author listed]. Randomised trial of intravenous atenolol among 16 027 cases of suspected acute myocardial infarction: ISIS-1. First International Study of Infarct Survival Collaborative Group. Lancet 1986;2:57–66
   PubMedGoogle Scholar
• Bansal BC, Agarwal AK, Rewari BB. Hypertension and cerebrovascular disease. J Indian Med Assoc 1999;97:226–32
   PubMedGoogle Scholar
• Blann AD, Lip GY, Islim IF, Beevers DG. Evidence of platelet activation in hypertension. J Hum Hypertens 1997;11:607–9
   PubMed Web of Science ®Google Scholar
• Lip GY, Li-Saw-Hee FL. Does hypertension confer a hypercoagulable state? J Hypertens 1998;16:913–6
   PubMed Web of Science ®Google Scholar
• Nakano KK. An overview of stroke. Epidemiology, classification, risk factors, clinical aspects. Postgrad Med 1986;80:82–7
   Google Scholar
• Sica DA, Schoolwerth AC. Part 1. Uric acid and losartan. Curr Opin Nephrol Hypertens 2002;11:475–82
   PubMed Web of Science ®Google Scholar
• Siragy HM. Angiotensin receptor blockers: how important is selectivity? Am J Hypertens 2002;15:1006–14
   PubMed Web of Science ®Google Scholar
• Puig JG, Mateos F, Buno A, Ortega R, Rodriguez F, Dal Re R. Effect of eprosartan and losartan on uric acid metabolism in patients with essential hypertension. J Hypertens 1999; 17:1033–9
   Google Scholar
• Puig JG, Ruilope LM. Uric acid as a cardiovascular risk factor in arterial hypertension. J Hypertens 1999;17:869–72
   PubMed Web of Science ®Google Scholar
• Puig JG, Torres R, Ruilope LM. AT1 blockers and uric acid metabolism: are there relevant differences? J Hypertens 2002;20\(Suppl 5):S29–31
   Google Scholar
• Pantev E, Stenman E, Wackenfors A, Edvinsson L, Malmsjo M. Comparison of the antagonistic effects of different angiotensin II receptor blockers in human coronary arteries. Eur J Heart Fail 2002;4:699–705
   Google Scholar
• Li P, Ferrario CM, Brosnihan KB. Nonpeptide angiotensin II antagonist losartan inhibits thromboxane A2-induced contractions in canine coronary arteries. J Pharmacol Exp Ther 1997;281: 1065–70
   Google Scholar
• Li P, Ferrario CM, Brosnihan KB. Losartan inhibits thromboxane A2-induced platelet aggregation and vascular constriction in spontaneously hypertensive rats. J Cardiovasc Pharmacol 1998;32: 198–205
   Google Scholar
• Lopez-Farre A, Sanchez dM, Monton M, Jimenez A, Lopez-Bloya A, Gomez J, et al. Angiotensin II AT(1) receptor antagonists and platelet activation. Nephrol Dial Transplant 2001;16\(Suppl 1):45–9
   Google Scholar
• Nunez A, Gomez J, Zalba LR, Monton M, Jimenez A, Velasco S, et al. Losartan inhibits in vitro platelet activation: comparison with candesartan and valsartan. J Renin Angiotensin Aldosterone Syst 2000;1:175–9
   PubMedGoogle Scholar
• Levy PJ, Yunis C, Owen J, Brosnihan KB, Smith R, Ferrario CM. Inhibition of platelet aggregability by losartan in essential hypertension. Am J Cardiol 2000;86:1188–92
   PubMed Web of Science ®Google Scholar
• Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. Collaborative Group on ACE Inhibitor Trials. JAMA 1995;273:1450–6
   PubMed Web of Science ®Google Scholar
• Doyle JC, Mottram DR, Stubbs H. Prescribing of ACE inhibitors for cardiovascular disorders in general practice. J Clin Pharm Ther 1998;23:133–6
   Google Scholar
• Houghton AR, Cowley AJ. Why are angiotensin converting enzyme inhibitors underutilised in the treatment of heart failure by general practitioners? Int J Cardiol 1997;59:7–10
   PubMed Web of Science ®Google Scholar
• Konstam MA. Improving clinical outcomes with drug treatment in heart failure: what have trials taught? Am J Cardiol 2003;91:9D–14D
   Google Scholar
• Sica DA. Pharmacotherapy in congestive heart failure. Prematurely terminated clinical trials and their application to cardiovascular medicine. Congest Heart Fail 2001;7:265–71
   Google Scholar
• Moore MA. Drugs that interrupt the rennin–angiotensin system should be among the preferred initial drugs to treat hypertension. J Clin Hypertens (Greenwich) 2003;5:137–44
   PubMedGoogle Scholar
• Moore MA. Improving the managed care of hypertension with angiotensin II antagonists. Am J Med Sci 2002;323:25–33
   PubMed Web of Science ®Google Scholar
• Cohn JN. Angiotensin receptor blockers and clinical trials in heart failure. Eur Heart J 2003;24:125–6
   PubMed Web of Science ®Google Scholar
• Pitt B, Segal R, Martinez FA, Meurers G, Cowley AJ, Thomas I, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 1997;349:747–52
   PubMed Web of Science ®Google Scholar
• Cowley AJ, Wiens BL, Segal R, Rich MW, Santanello NC, Dasbach EJ, et al. Randomised comparison of losartan vs. captopril on quality of life in elderly patients with symptomatic heart failure: the losartan heart failure ELITE quality of life substudy. Qual Life Res 2000;9:377–84
   Google Scholar
• Pitt B, Poole-Wilson PA, Segal R, Martinez FA, Dickstein K, Camm AJ, et al. Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: randomised trial – the Losartan Heart Failure Survival Study ELITE II. Lancet 2000;355:1582–7
   PubMed Web of Science ®Google Scholar
• Biollaz J, Brunner HR, Gavras I, Waeber B, Gavras H. Antihypertensive therapy with MK 421: angiotensin II–renin relationships to evaluate efficacy of converting enzyme blockade. J Cardiovasc Pharmacol 1982;4: 966–72
   Google Scholar
• Rousseau MF, Konstam MA, Benedict CR, Donckier J, Galanti L, Melin J, et al. Progression of left ventricular dysfunction secondary to coronary artery disease, sustained neurohormonal activation and effects of ibopamine therapy during long-term therapy with angiotensin-converting enzyme inhibitor. Am J Cardiol 1994;73:488–93
   PubMed Web of Science ®Google Scholar
• Roig E, Perez-Villa F, Morales M, Jimenez W, Orus J, Heras M, et al. Clinical implications of increased plasma angiotensin II despite ACE inhibitor therapy in patients with congestive heart failure. Eur Heart J 2000;21:53–7
   PubMed Web of Science ®Google Scholar
• Mazayev VP, Fomina IG, Kazakov EN, Sulimov VA, Zvereva TV, Lyusov VA, et al. Valsartan in heart failure patients previously untreated with an ACE inhibitor. Int J Cardiol 1998;65:239–46
   PubMed Web of Science ®Google Scholar
• Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med 2001;345:1667–75
   PubMed Web of Science ®Google Scholar
• McKelvie RS, Yusuf S, Pericak D, Avezum A, Burns RJ, Probstfield J, et al. Comparison of candesartan, enalapril, and their combination in congestive heart failure: randomized evaluation of strategies for left ventricular dysfunction (RESOLVD) pilot study. The RESOLVD Pilot Study Investigators. Circulation 1999;100:1056–64
   PubMed Web of Science ®Google Scholar
• Tsuyuki RT, Yusuf S, Rouleau JL, Maggioni AP, McKelvie RS, Wiecek EM, et al. Combination neurohormonal blockade with ACE inhibitors, angiotensin II antagonists and beta-blockers in patients with congestive heart failure: design of the Randomized Evaluation of Strategies for Left Ventricular Dysfunction (RESOLVD) Pilot Study. Can J Cardiol 1997;13:1166–74
   PubMed Web of Science ®Google Scholar
• Greenberg BH. Role of angiotensin receptor blockers in heart failure: not yet RESOLVD. Circulation 1999;100:1032–4
   PubMed Web of Science ®Google Scholar
• Swedberg K, Pfeffer M, Granger C, Held P, McMurray J, Ohlin G, et al. Candesartan in heart failure – assessment of reduction in mortality and morbidity (CHARM): rationale and design. Charm-Programme Investigators. J Card Fail 1999;5:276–82
   PubMedGoogle Scholar
• Granger CB, McMurray JJ, Yusuf S, Held P, Michelson EL, Olofsson B, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet 2003;362:772–6
   PubMed Web of Science ®Google Scholar
• McMurray JJ, Ostergren J, Swedberg K, Granger CB, Held P, Michelson EL, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003;362:767–71
   PubMed Web of Science ®Google Scholar
• Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003;362:777–81
   PubMed Web of Science ®Google Scholar
• Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003;362:759–66
   PubMed Web of Science ®Google Scholar
• Moore MA. Choosing initial antihypertensive drug therapy for the uncomplicated hypertensive patient. J Clin Hypertens (Greenwich) 2001;3:37–44
   PubMedGoogle Scholar
• Cohn JN. Lessons learned from the valsartan-heart failure trial (Val-HeFT): angiotensin receptor blockers in heart failure. Am J Cardiol 2002;90:992–3
   PubMed Web of Science ®Google Scholar
• White HD. Candesartan and heart failure: the allure of CHARM. Lancet 2003;362:754–5
   PubMed Web of Science ®Google Scholar
• Kohzuki M, Yasujima M, Kanazawa M, Yoshida K, Fu LP, Obara K, et al. Antihypertensive and renal-protective effects of losartan in streptozotocin diabetic rats. J Hypertens 1995;13:97–103
   PubMed Web of Science ®Google Scholar
• Lafayette RA, Mayer G, Park SK, Meyer TW. Angiotensin II receptor blockade limits glomerular injury in rats with reduced renal mass. J Clin Invest 1992;90:766–71
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456–62
   PubMed Web of Science ®Google Scholar
• Price DA, Hollenberg NK. Angiotensin receptor blockers in diabetic nephropathy. Curr Diab Rep 2001;1:267–74
   PubMedGoogle Scholar
• Lozano JV, Llisterri JL, Aznar J, Redon J. Losartan reduces microalbuminuria in hypertensive microalbuminuric type 2 diabetics. Nephrol Dial Transplant 2001;16(Suppl 1):85–9
   PubMedGoogle Scholar
• Remuzzi A, Fassi A, Bertani T, Perico N, Remuzzi G. ACE inhibition induces regression of proteinuria and halts progression of renal damage in a genetic model of progressive nephropathy. Am J Kidney Dis 1999;34:626–32
   Google Scholar
• Remuzzi A, Perico N, Sangalli F, Vendramin G, Moriggi M, Ruggenenti P, et al. ACE inhibition and ANG II receptor blockade improve glomerular size-selectivity in IgA nephropathy. Am J Physiol 1999;276:F457–F466
   PubMed Web of Science ®Google Scholar
• Border WA, Noble N. Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases. Semin Nephrol 2001;21:563–72
   PubMed Web of Science ®Google Scholar
• Ruoslahti E, Yamaguchi Y, Hildebrand A, Border WA. Extracellular matrix/growth factor interactions. Cold Spring Harb Symp Quant Biol 1992;57:309–15
   PubMedGoogle Scholar
• de Jong PE, Navis G, de Zeeuw D. Renoprotective therapy: titration against urinary protein excretion. Lancet 1999;354:352–3
   Google Scholar
• Parving HH, Hommel E, Jensen BR, Hansen HP. Long-term beneficial effect of ACE inhibition on diabetic nephropathy in normotensive type 1 diabetic patients. Kidney Int 2001;60:228–34
   PubMed Web of Science ®Google Scholar
• Nelson RG, Bennett PH, Beck GJ, Tan M, Knowler WC, Mitch WE, et al. Development and progression of renal disease in Pima Indians with non-insulin-dependent diabetes mellitus. Diabetic Renal Disease Study Group. N Engl J Med 1996;335:1636–42
   PubMedGoogle Scholar
• Rossing P, Hommel E, Smidt UM, Parving HH. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia 1994;37:511–6
   PubMed Web of Science ®Google Scholar
• Ahmad J, Siddiqui MA, Ahmad H. Effective postponement of diabetic nephropathy with enalapril in normotensive type 2 diabetic patients with microalbuminuria. Diabetes Care 1997;20: 1576–81
   Google Scholar
• Ravid M, Savin H, Jutrin I, Bental T, Katz B, Lishner M. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993;118:577–81
   PubMed Web of Science ®Google Scholar
• Amuchastegui SC, Azzollini N, Mister M, Pezzotta A, Perico N, Remuzzi G. Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J Am Soc Nephrol 1998;9:1948–55
   PubMed Web of Science ®Google Scholar
• Pollock DM, Divish BJ, Polakowski JS, Opgenorth TJ. Angiotensin II receptor blockade improves renal function in rats with reduced renal mass. J Pharmacol Exp Ther 1993;267:657–63
   PubMed Web of Science ®Google Scholar
• Remuzzi A, Perico N, Amuchastegui CS, Malanchini B, Mazerska M, Battaglia C, et al. Short- and long-term effect of angiotensin II receptor blockade in rats with experimental diabetes. J Am Soc Nephrol 1993;4:40–9
   PubMed Web of Science ®Google Scholar
• Ruggenenti P, Mosconi L, Sangalli F, Casiraghi F, Gambara V, Remuzzi G, et al. Glomerular size-selective dysfunction in NIDDM is not ameliorated by ACE inhibition or by calcium channel blockade. Kidney Int 1999;55:984–94
   PubMed Web of Science ®Google Scholar
• del Castillo D, Campistol JM, Guirado L, Capdevilla L, Martinez JG, Pereira P, et al. Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int 1998;68(Suppl):S135–9
   Google Scholar
• Gansevoort RT, de Zeeuw D, Shahinfar S, Redfield A, de Jong PE. Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease. J Hypertens 1994;12(Suppl):S37–S42
   Google Scholar
• Holdaas H, Hartmann A, Berg KJ, Lund K, Fauchald P. Renal effects of losartan and amlodipine in hypertensive patients with non-diabetic nephropathy. Nephrol Dial Transplant 1998;13:3096–102
   PubMed Web of Science ®Google Scholar
• Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345: 870–8
   Google Scholar
• Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–9
   PubMed Web of Science ®Google Scholar
• Lewis EJ, Hunsicker LG, Rodby RA. A clinical trial in type 2 diabetic nephropathy. Am J Kidney Dis 2001;38:S191–S194
   Google Scholar
• Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–60
   PubMed Web of Science ®Google Scholar
• Lewis EJ. The role of angiotensin II receptor blockers in preventing the progression of renal disease in patients with type 2 diabetes. Am J Hypertens 2002;15:123S–8S
   Google Scholar
• Brenner BM, Cooper ME, Zeeuw DD, Grunfeld JP, Keane WF, Kurokawa K, et al. The losartan renal protection study – rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Syst 2000;1:328–35
   PubMedGoogle Scholar
• Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, et al. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 2000;15:487–97
   PubMed Web of Science ®Google Scholar
• Neal B, MacMahon S, Chapman N. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. Blood Pressure Lowering Treatment Trialists’ Collaboration. Lancet 2000;356:1955–64
   Google Scholar
• Lindholm LH, Dahlof B, Edelman JM, Ibsen H, Borch-Johnsen K, Olsen MH, et al. Effect of losartan on sudden cardiac death in people with diabetes: data from the LIFE study. Lancet 2003;362:619–20
   Google Scholar
• [No author listed]. 2002 annual report: ESRD clinical performance measures project. Am J Kidney Dis 2003;42:1–96
   Google Scholar
• Hostetter TH, Lising M. National kidney disease education program. J Am Soc Nephrol 2003;14:S114–S116
   PubMed Web of Science ®Google Scholar
• Jones CA. Hypertension and renal dysfunction: NHANES III. J Am Soc Nephrol 2003;14:S71–S75
   PubMed Web of Science ®Google Scholar
• Herman WH, Shahinfar S, Carides GW, Dasbach EJ, Gerth WC, Alexander CM, et al. Losartan reduces the costs associated with diabetic end-stage renal disease: The RENAAL study economic evaluation. Diabetes Care 2003;26:683–7
   PubMed Web of Science ®Google Scholar
• Nakao N, Yoshimura A, Morita H, Takada M, Kayano T, Ideura T. Combination treatment of angiotensin-II receptor blocker and angiotensin-converting-enzyme inhibitor in non-diabetic renal disease (COOPERATE): a randomised controlled trial. Lancet 2003;361:117–24
   PubMed Web of Science ®Google Scholar
• Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145–53
   PubMed Web of Science ®Google Scholar
• Ferrario CM, Levy P. Sexual dysfunction in patients with hypertension: implications for therapy. J Clin Hypertens (Greenwich) 2002;4:424–32
   PubMedGoogle Scholar
• Chan P, Liu JC, Tong YC, Chen YJ, Wang CC, Tomlinson B, et al. Effects of losartan on the sexual behavior of male rats. Pharmacology 1999;58:132–9
   PubMed Web of Science ®Google Scholar
• Kifor I, Williams GH, Vickers MA, Sullivan MP, Jodbert P, Dluhy RG. Tissue angiotensin II as a modulator of erectile function. I. Angiotensin peptide content, secretion and effects in the corpus cavernosum. J Urol 1997;157:1920–5
   Google Scholar
• Alderman MH. Serum uric acid and cardiovascular disease risk. Ann Intern Med 2000;132:591
   PubMedGoogle Scholar
• Breckenridge A. Hypertension and hyperuricaemia. Lancet 1966;1:15–8
   PubMed Web of Science ®Google Scholar
• Burnier M, Pechere-Bertschi A, Nussberger J, Waeber B, Brunner HR. Studies of the renal effects of angiotensin II receptor blockade: the confounding factor of acute water loading on the action of vasoactive systems. Am J Kidney Dis 1995;26:108–15
   PubMed Web of Science ®Google Scholar
• Hamada T, Hisatome I, Kinugasa Y, Matsubara K, Shimizu H, Tanaka H, et al. Effect of the angiotensin II receptor antagonist losartan on uric acid and oxypurine metabolism in healthy subjects. Intern Med 2002;41:793–7
   PubMed Web of Science ®Google Scholar
• Minghelli G, Seydoux C, Goy JJ, Burnier M. Uricosuric effect of the angiotensin II receptor antagonist losartan in heart transplant recipients. Transplantation 1998;66:268–71
   PubMed Web of Science ®Google Scholar
• Sasaki M, Fujimura A, Harada K, Sunaga K, Ebihara A. Clinical pharmacology of multiple-dose losartan, an angiotensin II receptor antagonist, in patients with essential hypertension. J Clin Pharmacol 1996;36:403–8
   Google Scholar
• Liberopoulos E, Christides D, Elisaf M. Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricemia and gout. J Hypertens 2002;20:347
   Google Scholar
• Manolis AJ, Grossman E, Jelakovic B, Jacovides A, Bernhardi DC, Cabrera WJ, et al. Effects of losartan and candesartan monotherapy and losartan/hydrochlorothiazide combination therapy in patients with mild to moderate hypertension. Losartan Trial Investigators. Clin Ther 2000;22:1186–203
   Google Scholar
• Sayin T, Doven O, Akyurek O, Dincer I. Neutral effect of valsartan on serum uric acid and renal function tests. J Hum Hypertens 2001;15:435–6
   PubMed Web of Science ®Google Scholar
• Nikas S, Rizos E, Milionis H, Bairaktari E, Kalaitzidis R, Siamopoulos K, et al. The effects of the addition of losartan on uric acid metabolism in patients receiving indapamide. J Renin Angiotensin Aldosterone Syst 2000;1:289–91
   PubMedGoogle Scholar
• Soffer BA, Wright JT, Jr., Pratt JH, Wiens B, Goldberg AI, Sweet CS. Effects of losartan on a background of hydrochlorothiazide in patients with hypertension. Hypertension 1995;26:112–7
   Google Scholar
• Fukuhara M, Neves LA, Li P, Diz DI, Ferrario CM, Brosnihan KB. The angiotensin II AT1 receptor antagonist irbesartan prevents thromboxane A2-induced vasoconstriction in the rat hind-limb vascular bed in vivo. J Hypertens 2001;19:561–6
   PubMed Web of Science ®Google Scholar
• Li P, Fukuhara M, Diz DI, Ferrario CM, Brosnihan KB. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation. J Pharmacol Exp Ther 2000;292: 238–46
   Google Scholar
• Bertolino F, Valentin JP, Maffre M, Bessac AM, John GW. TxA2 receptor activation elicits organ-specific increases in microvascular permeability in the rat. Am J Physiol 1995;268:R366–R374
   Google Scholar
• Bertolino F, Valentin JP, Maffre M, Jover B, Bessac AM, John GW. Losartan prevents pulmonary hypertension induced by a thromboxane A2 analog. Arch Mal Coeur Vaiss 1994;87:971–4
   PubMedGoogle Scholar
• Bertolino F, Valentin JP, Maffre M, Jover B, Bessac AM, John GW. Prevention of thromboxane A2 receptor-mediated pulmonary hypertension by a nonpeptide angiotensin II type 1 receptor antagonist. J Pharmacol Exp Ther 1994;268:747–52
   PubMed Web of Science ®Google Scholar
• Chlopicki S, Koda M, Chabielska E, Buczko W, Gryglewski RJ. Antiplatelet action of losartan involves TXA2 receptor antagonism but not TXA2 synthase inhibition. J Physiol Pharmacol 2000;51: 715–22
   Google Scholar
• Kramer C, Sunkomat J, Witte J, Luchtefeld M, Walden M, Schmidt B, et al. Angiotensin II receptor-independent antiinflammatory and antiaggregatory properties of losartan: role of the active metabolite EXP3179. Circ Res 2002;90:770–6
   PubMed Web of Science ®Google Scholar
• Sadoshima J. Novel AT(1) receptor-independent functions of losartan. Circ Res 2002;90:754–6
   PubMed Web of Science ®Google Scholar
• Llisterri JL, Lozano Vidal JV, Aznar VJ, Argaya RM, Pol BC, Sanchez Zamorano MA, et al. Sexual dysfunction in hypertensive patients treated with losartan. Am J Med Sci 2001;321:336–41
   PubMed Web of Science ®Google Scholar
• Fogari R, Preti P, Derosa G, Marasi G, Zoppi A, Rinaldi A, et al. Effect of antihypertensive treatment with valsartan or atenolol on sexual activity and plasma testosterone in hypertensive men. Eur J Clin Pharmacol 2002;58:177–80
   PubMed Web of Science ®Google Scholar
• Fogari R, Zoppi A, Poletti L, Marasi G, Mugellini A, Corradi L. Sexual activity in hypertensive men treated with valsartan or carvedilol: a crossover study. Am J Hypertens 2001;14:27–31
   PubMed Web of Science ®Google Scholar
• Tedesco MA, Ratti G, Mennella S, Manzo G, Grieco M, Rainone AC, et al. Comparison of losartan and hydrochlorothiazide on cognitive function and quality of life in hypertensive patients. Am J Hypertens 1999;12:1130–4
   PubMed Web of Science ®Google Scholar
• Bloom BS. Continuation of initial antihypertensive medication after 1 year of therapy. Clin Ther 1998;20:671–81
   PubMed Web of Science ®Google Scholar
• Bloom BS. Daily regimen and compliance with treatment. BMJ 2001;323:647
   PubMed Web of Science ®Google Scholar
• Benedict CR. Safe and effective management of hypertension with fixed-dose combination therapy: focus on losartan plus hydrochlorothiazide. Int J Clin Pract 2000;54:48–54
   PubMed Web of Science ®Google Scholar
• Conlin PR, Spence JD, Williams B, Ribeiro AB, Saito I, Benedict C, et al. Angiotensin II antagonists for hypertension: are there differences in efficacy? Am J Hypertens 2000;13:418–26
   PubMed Web of Science ®Google Scholar
• 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003;21: 1011–53
   Google Scholar